Biologic Treatment Options for Retinal Neovascularization in Behcet's Disease

Markomichelakis N. N. , Aissopou E. K. , Maselos S., Tugal-Tutkun I. , Sfikakis P. P.

OCULAR IMMUNOLOGY AND INFLAMMATION, vol.27, no.1, pp.51-57, 2019 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 27 Issue: 1
  • Publication Date: 2019
  • Doi Number: 10.1080/09273948.2017.1332228
  • Journal Indexes: Science Citation Index Expanded, Scopus
  • Page Numbers: pp.51-57


Purpose: Relapsing ocular inflammation occurs in about 70% of patients with Behcet's disease (BD) and can lead to permanent loss of vision. Neovascularization of the optic disc (NVD) or elsewhere in the retina (NVE) is a relatively uncommon but severe complication that lacks standardized treatment. Methods: We report on the therapeutic use of anti-TNF monoclonal antibodies for BD-associated NVD and NVE in one pediatric patient (subcutaneous adalimumab) and one young man (intravenous infliximab). Also, we review the previously published experience on biologic therapeutic options, namely anti-TNF agents and interferon-alpha in a total of three and eight patients, respectively. Results: A fast-onset therapeutic effect was observed in both patients leading to complete regression of neovascularizations. Conclusions: Both options may lead to regression of neovascularization, thus preventing loss of vision, but comparative studies need to determine the optimal treatment for this sight-threatening complication of BD.